非治療性生物分子市場規模、佔有率和成長分析：按產品類型、原料、應用、最終用戶和地區分類－2026-2033年產業預測

2024 年全球非治療性生物分子市場價值為 51.8 億美元，預計到 2025 年將成長至 58.2 億美元，到 2033 年將成長至 148.4 億美元，在預測期（2026-2033 年）內複合年成長率為 12.4%。

全球非治療性生物分子市場涵蓋多種產品，包括酵素、抗體、核酸以及其他用於診斷、食品安全、化妝品和工業應用的化合物。與傳統化學物質相比，這些生物分子在特異性和永續性方面具有顯著優勢，從而提升了其市場重要性。重組DNA技術的進步降低了生產成本，加速了主要公司診斷工具和生物基防腐劑的商業化進程。不斷成長的消費者需求和日益嚴格的有害物質監管進一步推動了市場成長，使該市場發展成為一個價值數十億美元的產業。對診斷解決方案（尤其是酵素免疫分析法和抗體生物感測器）的需求不斷成長，正在推動生物製造領域的投資，並為利基企業拓展其產品線、應用於不同領域的新機會創造了條件。

全球非治療性生物分子市場的成長要素

非治療性生物分子在食品保鮮、化妝品和農業等各領域的應用日益廣泛，推動了穩定的市場需求。製造商越來越重視天然來源的功能性成分，這些成分不僅能提升產品性能，還能滿足消費者對永續性和安全性的偏好。這一趨勢刺激了對產能的投資，並鼓勵對新型提取技術進行創新研究，從而擴大市場准入。此外，這些進展也促進了生技公司與終端用戶市場之間的合作，加速了技術轉移，並增強了投資者信心，從而形成良性循環，支持市場成長和產品多元化。

全球非治療性生物分子市場面臨的限制因素

由於法律規範不一致和不同司法管轄區分類不明確，全球非治療性生物分子市場面臨嚴峻挑戰。這種情況給生產商帶來不確定性，導致核准流程延長、遵循成本增加，並阻礙了新產品的上市。缺乏統一標準不僅阻礙了跨境貿易，也抑制了對大規模生產設施的投資。因此，企業被迫將資源用於應對複雜的法律要求，而非專注於創新，最終阻礙了整體市場成長。此外，持續的安全評估要求也給中小企業帶來了額外的負擔，限制了尋求將創新生物分子解決方案推向市場的新參與企業的機會。

非治療性生物分子的全球市場趨勢

全球非治療性生物分子市場正經歷著向精準酶工程的顯著轉變，其特點是先進的蛋白質設計平台已廣泛應用。這些平台利用機器學習、高通量篩檢和定向進化等先進調查方法，實現酶活性、穩定性和基材特異性的客製化。在永續性和成本效益至關重要的應用領域，例如工業催化劑、生質燃料生產和食品加工，這一趨勢尤其顯著。隨著企業日益追求競爭優勢，生技公司、學術機構和下游製造商之間正在建立策略合作夥伴關係，而客製化生物分子正逐漸成為市場創新和成長的關鍵要素。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球非治療性生物分子市場規模：依產品類型分類

• 蛋白質
  • 酵素
  • 重組蛋白
• 核酸
  • DNA
  • RNA
• 胜肽
• 碳水化合物和Glico
• 脂質
• 其他

全球非治療性生物分子市場規模：依原料分類

• 自然的
• 合成
• 重組

全球非治療性生物分子市場規模：按應用領域分類

• 研究與學術
• 診斷
• 工業生物技術
• 食品/飲料
• 化妝品和個人護理
• 農業
• 環境領域

全球非治療性生物分子市場規模：依最終用戶分類

• 研究機構和大學
• 生技公司
• 診斷檢查室
• 工業製造商
• 食品和飲料公司
• 化妝品製造商

全球非治療性生物分子市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Thermo Fisher Scientific Inc.
• Merck KGaA
• Danaher Corporation
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN NV
• F. Hoffmann-La Roche Ltd
• Illumina, Inc.
• Sartorius AG
• Lonza Group AG
• Bio-Techne Corporation
• New England Biolabs, Inc.
• Promega Corporation
• Takara Bio Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc.
• Standard BioTools Inc.
• Revvity, Inc.
• Charles River Laboratories International, Inc.
• GenScript Biotech Corporation

結論與建議

Global Non-Therapeutic Biomolecules Market size was valued at USD 5.18 Billion in 2024 and is poised to grow from USD 5.82 Billion in 2025 to USD 14.84 Billion by 2033, growing at a CAGR of 12.4% during the forecast period (2026-2033).

The global market for non-therapeutic biomolecules encompasses a variety of products, including enzymes, antibodies, nucleic acids, and other compounds utilized in diagnostics, food safety, cosmetics, and industrial applications. These biomolecules offer distinct advantages in terms of specificity and sustainability over conventional chemicals, driving their market relevance. With advancements in recombinant DNA technology reducing production costs, major companies have facilitated the commercialization of diagnostic tools and bio-based preservatives. Increasing consumer demand and stricter regulations surrounding hazardous substances have further propelled market growth, evolving it into a multi-billion-dollar sector. The rising need for diagnostic solutions, particularly enzyme-linked assays and antibody-based biosensors, fosters investment in biomanufacturing and presents fresh opportunities for niche players to expand their offerings across diverse applications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Therapeutic Biomolecules market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Therapeutic Biomolecules Market Segments Analysis

Global non-therapeutic biomolecules market is segmented by product type, source, application, end user and region. Based on product type, the market is segmented into proteins, nucleic acids, peptides, carbohydrates & glycoconjugates, lipids and other biomolecules. Based on source, the market is segmented into natural, synthetic and recombinant. Based on application, the market is segmented into research & academic use, diagnostics, industrial biotechnology, food & beverage, cosmetics & personal care, agriculture and environmental applications. Based on end user, the market is segmented into research institutes & universities, biotechnology companies, diagnostic laboratories, industrial manufacturers, food & beverage companies and cosmetics manufacturers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Therapeutic Biomolecules Market

The growing application of non-therapeutic biomolecules across various sectors such as food preservation, cosmetics, and agriculture is driving consistent demand in the market. Manufacturers are increasingly prioritizing natural and functional ingredients that not only improve product performance but also align with consumer preferences for sustainability and safety. This trend encourages investment in production capabilities and inspires innovative research into new extraction techniques that broaden market accessibility. Additionally, these advancements promote partnerships between biotech companies and their end-user markets, expedite the transfer of technology, and enhance investor confidence, creating a positive feedback loop that fuels both market growth and product diversity.

Restraints in the Global Non-Therapeutic Biomolecules Market

The global non-therapeutic biomolecules market faces significant challenges due to inconsistent regulatory frameworks and unclear classification across various jurisdictions. This situation generates uncertainty for manufacturers, resulting in extended approval processes, heightened compliance expenses, and reluctance to introduce new products. The absence of harmonized standards not only obstructs cross-border trade but also deters investment in large-scale production facilities. Consequently, companies are compelled to divert resources toward navigating intricate legal requirements instead of concentrating on innovation, which ultimately hampers overall market expansion. Furthermore, the need for ongoing safety evaluations imposes additional pressures on smaller entities, restricting opportunities for new entrants aiming to bring innovative biomolecular solutions to market.

Market Trends of the Global Non-Therapeutic Biomolecules Market

The Global Non-Therapeutic Biomolecules market is experiencing a significant shift towards precision enzyme engineering, characterized by the widespread adoption of cutting-edge protein design platforms. These platforms leverage advanced methodologies such as machine learning, high-throughput screening, and directed evolution, allowing for the customization of enzyme activities, stability, and substrate specificities. This trend is particularly pronounced in applications like industrial catalysis, bio-fuel production, and food processing, where sustainability and cost efficiency are paramount. As businesses increasingly seek competitive advantages, strategic collaborations between biotech companies, academic institutions, and downstream manufacturers are emerging, positioning customized biomolecules as essential components of innovation and growth in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Non-Therapeutic Biomolecules Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Proteins
  • Enzymes
  • Recombinant Proteins
• Nucleic Acids
  • DNA
  • RNA
• Peptides
• Carbohydrates & Glycoconjugates
• Lipids
• Other Biomolecules

Global Non-Therapeutic Biomolecules Market Size by Source & CAGR (2026-2033)

• Market Overview
• Natural
• Synthetic
• Recombinant

Global Non-Therapeutic Biomolecules Market Size by Application & CAGR (2026-2033)

• Market Overview
• Research & Academic Use
• Diagnostics
• Industrial Biotechnology
• Food & Beverage
• Cosmetics & Personal Care
• Agriculture
• Environmental Applications

Global Non-Therapeutic Biomolecules Market Size by End User & CAGR (2026-2033)

• Market Overview
• Research Institutes & Universities
• Biotechnology Companies
• Diagnostic Laboratories
• Industrial Manufacturers
• Food & Beverage Companies
• Cosmetics Manufacturers

Global Non-Therapeutic Biomolecules Market Size & CAGR (2026-2033)

• North America (Product Type, Source, Application, End User)
  • US
  • Canada
• Europe (Product Type, Source, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Source, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Source, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Source, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• New England Biolabs, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Nanopore Technologies plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Standard BioTools Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revvity, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations